These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25474442)

  • 21. Diagnostic approach and treatment of cutaneous lupus erythematosus.
    Sticherling M; Bonsmann G; Kuhn A
    J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The different faces of cutaneous lupus erythematosus.
    Renner R; Sticherling M
    G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus].
    Sticherling M
    Z Rheumatol; 2013 Jun; 72(5):429-35. PubMed ID: 23743985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of "refractory" skin disease in patients with lupus erythematosus.
    Callen JP
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):767-84. PubMed ID: 16150402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study.
    Madan V; August PJ; Chalmers RJ
    Clin Exp Dermatol; 2010 Jan; 35(1):27-30. PubMed ID: 19549244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.
    Kuhn A; Sigges J; Biazar C; Ruland V; Patsinakidis N; Landmann A; Amler S; Bonsmann G;
    Br J Dermatol; 2014 Sep; 171(3):571-9. PubMed ID: 24673427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature.
    Klebes M; Wutte N; Aberer E
    Dermatology; 2016; 232(1):91-6. PubMed ID: 26606129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the management of cutaneous lupus erythematosus.
    Callen JP
    Br J Dermatol; 2004 Oct; 151(4):731-6. PubMed ID: 15491411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertrophic lupus erythematosus: case report.
    Bardek I; Basta-Juzbasić A; Marinović B; Bukvić Mokos Z; Milavec-Puretić V
    Acta Dermatovenerol Croat; 2009; 17(2):134-8. PubMed ID: 19595272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bullous systemic lupus erythematosus: response to dapsone in two patients.
    Sirka CS; Padhi T; Mohanty P; Patel DK; Parida PR; Kar CR
    Indian J Dermatol Venereol Leprol; 2005; 71(1):54-6. PubMed ID: 16394370
    [No Abstract]   [Full Text] [Related]  

  • 37. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
    Yan D; Borucki R; Sontheimer RD; Werth VP
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.
    Kieu V; O'Brien T; Yap LM; Baker C; Foley P; Mason G; Prince HM; McCormack C
    Australas J Dermatol; 2009 Aug; 50(3):202-6. PubMed ID: 19659984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement.
    Hanjani NM; Nousari CH
    Arch Dermatol; 2002 Dec; 138(12):1616-8. PubMed ID: 12472362
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.